Risk factors

Exelixis (EXEL) risk factors

Item 1A of every Exelixis, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open EXEL in Gloom →
Exelixis' chart, financials and news, free in your browser.Open EXEL in Gloom →
  • FY2025 10-K risk factors
    26 risks1 new1 dropped7 reworded

    Exelixis updated financial figures, highlighting net income growth to $782.6 million for 2025.

    Filed Feb 10, 2026
  • FY2024 10-K risk factors
    26 risks

    Exelixis depends heavily on CABOMETYX commercial success and its oncology pipeline expansion.

    Filed Feb 11, 2025